Connect with us

CBD News

GW Pharmaceuticals (GWPH) Dealt Another Blow in UK Due to Epidiolex CBD Epilepsy Drug Cost



GW Pharmaceuticals (GWPH) Dealt Another Blow in UK Due to Epidiolex CBD Epilepsy Drug Cost

The United Kingdom’s National Institute for Health and Care Excellence (NICE), which advises to the National Health Services (NHS) concerning healthcare costs and qualities, has released a draft guidance on GW Pharmaceuticals’ Epidyolex (cannabidiol) treatment for conditions such as Lennox-Gastaut and Dravet syndromes.

The draft guidance ruled against the use of GW Pharmaceuticals’ Epidyolex by the NHS. Despite the advisory against its use, the guidance also indicates that the agency will work with the company on the issues that it pointed out in its evaluation. The Director of the Center for Health Technology Evaluation at NICE stated:

“even though the committee accepted that the evidence shows that [Epidyolex] with clobazam reduces seizure frequency, its long-term efficacy is unknown, and the committee was not convinced about the way the company had modelled the effect on people living longer or having a better quality of life.”

Apparently, one of the main issues concerning the drug was cost. Boysen also stated:

“we are committed to working with the company to resolve the economic modelling issues identified by the committee, and to help them understand what they may need to do to mitigate the cost of [Epidyolex] to the NHS.”

In addition to the cost, another issue highlighted by the review committee, according to Seeking Alpha, is that the evidence indicated that when the Epidyolex drug was combined with clobazam, it may reduce the frequency of seizures, but ultimately the long-term effectiveness is unknown, which also led to questions as to how the drug impacted patients’ longevity and quality of life.

Alexander G. Smith is an experienced researcher for both new health topics and science coverage. Being a seasoned Human Resources professional, his content writing skills have sharpened in the areas of workplace and business topics but loves to focus on wellness and natural alternatives here at TOC.

Continue Reading

Ultimate CBD Guide


ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email

Copyright © 2020 | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.